1,4-二叔丁基2-(氨基甲基)哌嗪-1,4-二羧酸 | 1256815-07-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1,4-二叔丁基2-(氨基甲基)哌嗪-1,4-二羧酸
• 英文名称: di-tert-butyl 2-(aminomethyl)piperazine-1,4-dicarboxylate
• 英文别名: ditert-butyl 2-(aminomethyl)piperazine-1,4-dicarboxylate
• CAS: 1256815-07-2
• 化学式: C₁₅H₂₉N₃O₄
• 分子量: 315.413
• InChiKey: XJELTUFOFGNOTB-UHFFFAOYSA-N

物化性质

• 熔点：
  92-93 °C
• 沸点：
  399.8±17.0 °C(Predicted)
• 密度：
  1.096±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  85.1
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1,4-二叔丁基2-(氨基甲基)哌嗪-1,4-二羧酸 在 盐酸 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 mineral oil 为溶剂， 生成 hexahydro-2-(3-cyanobenzyl)-imidazo[1,5-a]pyrazin-3-one
  参考文献：
  名称：

  新型2-取代咪唑并吡嗪酮衍生物的便捷合成

  摘要：

  摘要 以市售的哌嗪-2-羧酸为原料，制备了一系列新型的2-芳基和2-苄基取代的咪唑并吡嗪酮。通过简单的 Buchwald-Hartwig 偶联反应获得中间体 5a-g，并研究了催化剂、碱和溶剂对偶联反应的影响。偶联反应的最佳反应条件为PdCl2(dppf)/NaO-t-Bu/甲苯。图形概要

  DOI：

  10.1080/00397911.2010.525774
• 作为产物：
  描述：

  2-(羟甲基)-1,4-哌嗪二羧酸二叔丁酯 在 偶氮二甲酸二异丙酯 、 三苯基膦 、 甲胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 6.0h， 生成 1,4-二叔丁基2-(氨基甲基)哌嗪-1,4-二羧酸
  参考文献：
  名称：

  新型2-取代咪唑并吡嗪酮衍生物的便捷合成

  摘要：

  摘要 以市售的哌嗪-2-羧酸为原料，制备了一系列新型的2-芳基和2-苄基取代的咪唑并吡嗪酮。通过简单的 Buchwald-Hartwig 偶联反应获得中间体 5a-g，并研究了催化剂、碱和溶剂对偶联反应的影响。偶联反应的最佳反应条件为PdCl2(dppf)/NaO-t-Bu/甲苯。图形概要

  DOI：

  10.1080/00397911.2010.525774

文献信息

• Metallo-beta-lactamase inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10221163B2

  公开（公告）日：2019-03-05

  The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

  本发明涉及式 I 的金属-β-内酰胺酶抑制剂化合物：及其药学上可接受的盐，其中 Z、RA、X1、X2 和 R1 如本文所定义。本发明还涉及组合物，其包含本发明的金属-β-内酰胺酶抑制剂化合物或其药学上可接受的盐，以及药学上可接受的载体，可选择与β-内酰胺抗生素和/或β-内酰胺酶抑制剂结合使用。本发明进一步涉及治疗细菌感染的方法，包括向患者施用治疗有效量的本发明化合物，与治疗有效量的一种或多种β-内酰胺类抗生素联合使用，也可选择与一种或多种β-内酰胺酶抑制剂化合物联合使用。本发明的化合物在本文所述的克服抗生素耐药性的方法中是有用的。
• 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
  申请人：Revolution Medicines, Inc.

  公开号：US10590090B2

  公开（公告）日：2020-03-17

  The present disclosure is directed to inhibitors of SHP2, such as pyrazine compounds, and their use in the treatment of disease associated with SHP2 modulation, such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. Also disclosed are pharmaceutical compositions comprising the same.

  本公开涉及 SHP2 的抑制剂，例如吡嗪化合物，以及它们在治疗与 SHP2 调节相关的疾病中的用途，例如努南综合征、豹综合征、幼年骨髓单核细胞白血病、神经母细胞瘤、黑色素瘤、急性髓性白血病以及乳腺癌、肺癌和结肠癌。还公开了包含上述成分的药物组合物。
• Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors
  作者：Yanyun Zhu、Shuang Xia、Mingjie Zhu、Weiyin Yi、Jiagao Cheng、Gonghua Song、Zhong Li、Peng Lu

  DOI：10.1016/j.ejmech.2010.08.002

  日期：2010.11

  A series of novel imidazopyrazinone derivatives were synthesized and evaluated with regard to their ability to inhibit dipeptidyl peptidase IV (DPP-IV) in vitro. Of these compounds (2R)-4-oxo-4-[2-(3-carbamoylbenzyl)-hexahydro-3-oxoimidazo [1,5-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine fumaric acid (17h, IC50 = 78 nM) was shown to effectively inhibit the activity of the dipeptidyl peptidase IV enzyme. Molecular docking studies were also performed to illustrate the binding mode of compounds 15c and 17h. Favorable interactions were identified from the binding of inhibitor 15c with DPP-IV. By analogy to the binding mode of compound 15c, it seems that the introduction of a substituted benzyl moiety onto the imidazopyrazinone could remarkably improve the inhibitory activity of compound 17h. (C) 2010 Elsevier Masson SAS. All rights reserved.
• 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3313832A1

  公开（公告）日：2018-05-02
• METALLO-BETA-LACTAMASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20180244656A1

  公开（公告）日：2018-08-30

  The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, R A , X 1 , X 2 and R 1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.